Table 2.
Symptoms and diagnostic findings after the primary cardiac resynchronization therapy procedure, compared to after repositioning of the left ventricular lead
| Pre implant | After first implant | Change | Pre LV repositioning | After LV repositioning | Change | P value (for difference in delta) | |
|---|---|---|---|---|---|---|---|
| NYHA class (average) | +0.2 ± 0.4 | -0.5 ± 0.5 | <.001 | ||||
| Class II | 12 (48%) | 8 (32%) | 4 (16%) | 17 (68%) | |||
| Class III | 13 (52%) | 17 (68%) | 21 (84%) | 8 (32%) | |||
| Patient-assessed response | <.001 | ||||||
| Deterioration | 3 (12%) | 0 | |||||
| No change | 16 (64%) | 8 (32%) | |||||
| Some positive effect | 6 (24%) | 4 (16%) | |||||
| Marked positive effect | 0 | 12 (48%) | |||||
| Not evaluated | 0 | 1 (4%) | |||||
| LVEF (%) | 28 [22–31] | 28 [22–30] | 0 [-2 to +7] | 25 [22–30] | 30 [25–35] | +5 [+2 to +11] | .01 |
| QRS duration (ms) | 168 [154–182] | 176 [151–190] | +2 [-23 to +22] | 180 [170–196] | 148 [136–163] | -36 [-44 to -8] | <.001 |
| NT-proBNP (ng/L) | 1104 [612–2007] | 2192 [986–2708] | +359 [-147 to +1628] | 2448 [924–3884] | 1977 [686–2688] | -615 [-2837 to +121] | .03 |
| Biventricular pace (%) | 97.5 [87–99] | 97.5 [88–99] | .9 |
Results are based on N = 25 patients; data are presented as n (%) or mean [interquartile range].
LV = left ventricular; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.